Company intelligence / Profile preview
Biond Biologics
Israelbiondbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biond Biologics has advanced two main immunotherapy candidates, BND‑22 and BND‑35, into Phase 1/2 clinical trials in patients with advanced solid tumors. Both are novel immune checkpoint inhibitors targeting previously untapped immune evasion mechanisms. Early results focus on safety, tolerability, pharmacokinetics/dynamics, and preliminary anti-tumor activity. The company also has several preclinical programs leveraging its INspire platform to target both intra‑ and extracellular pathways relevant to cancer immunology.[5][6]
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodies (mAbs)Drug conjugatesNanobodies[8]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Sanofi – partnered on BND–22 with $125M upfront payment plus up to $1 billion in milestones and royalties.[7]
Beyond the preview
Go deeper on Biond Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biond Biologics.